Propel Bio Management, LLC
- SEC CIK
- 0001969764
- Latest filing
- Aug 13, 2026
Holdings in Q3 2024
Holdings as of Sep 30, 2024, filed Nov 13, 2024. Long positions only; changes compare share counts with Q2 2024.
- Positions
- 21
- −3 vs. Q2 2024
- Portfolio value
- $172.4M
- +$18.2M (+11.8%) vs. Q2 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| APLTApplied Therapeutics, Inc. | COM | 6,567,858 | $55.8M | 32.4% | 00.0% | Unchanged | History |
| PAGPPlains GP Holdings LP | LTD PARTNR INT A | 1,272,360 | $23.5M | 13.7% | −100,000−7.3% | Reduced | History |
| PHATPhathom Pharmaceuticals, Inc. | COM | 869,927 | $15.7M | 9.1% | 00.0% | Unchanged | History |
| ACHVAchieve Life Sciences, Inc. | COM | 2,453,092 | $11.6M | 6.7% | 00.0% | Unchanged | History |
| TCRXTScan Therapeutics, Inc. | COM | 2,087,139 | $10.4M | 6.0% | 00.0% | Unchanged | History |
| AKROAkero Therapeutics, Inc. | COM | 343,729 | $9.86M | 5.7% | +15,977+4.9% | Added | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 43,032 | $9.13M | 5.3% | 00.0% | Unchanged | History |
| Avidity Biosciences, Inc.05370A108 | COM | 178,500 | $8.20M | 4.8% | 00.0% | Unchanged | – |
| ARDXArdelyx, Inc. | COM | 1,070,947 | $7.38M | 4.3% | +146,364+15.8% | Added | History |
| TSATTelesat Corp | CL A & CL B SHS | 365,781 | $4.82M | 2.8% | 00.0% | Unchanged | History |
| ABEOAbeona Therapeutics Inc. | COM NEW | 624,022 | $3.94M | 2.3% | −624,022−50.0% | Reduced | History |
| KYMRKymera Therapeutics, Inc. | COM | 56,359 | $2.67M | 1.5% | 00.0% | Unchanged | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 133,259 | $2.57M | 1.5% | +50,000+60.1% | Added | History |
| KURAKura Oncology, Inc. | COM | 130,000 | $2.54M | 1.5% | 00.0% | Unchanged | History |
| ZVRAZevra Therapeutics, Inc. | COM NEW | 179,874 | $1.25M | 0.7% | +179,874 | New | History |
| EIGREiger BioPharmaceuticals, Inc. | COM NEW | 146,381 | $1.24M | 0.7% | 00.0% | Unchanged | History |
| LONALeonaBio, Inc. | COM | 1,492,792 | $665.8K | 0.4% | 00.0% | Unchanged | History |
| CMPSCOMPASS Pathways plc | SPONSORED ADS | 80,000 | $504.0K | 0.3% | +80,000 | New | History |
| VRCAVerrica Pharmaceuticals Inc. | COM | 344,937 | $500.2K | 0.3% | −80,000−18.8% | Reduced | History |
| Maat Pharma SacaF5888J116 | COMM | 2,397 | $17.8K | <0.1% | +2,397 | New | – |
| Contra Chinook Therapeu169CVR016 | COM | 79,357 | $9.75K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q2 2024 (6)
Positions held at the end of Q2 2024 that are gone from this filing.
| Security | Class | Shares in Q2 2024 | Value in Q2 2024 | % of portfolio in Q2 2024 | History |
|---|---|---|---|---|---|
| FULCFulcrum Therapeutics, Inc. | COM | 750,000 | $4.65M | 3.0% | History |
| KYNKayne Anderson Energy Infrastructure Fund, Inc. | COM | 147,033 | $1.52M | 1.0% | History |
| TRVITrevi Therapeutics, Inc. | COM | 260,000 | $774.8K | 0.5% | History |
| Fidelity Inv Mmtrsy 1 680X9USDFIDT | COMM | 317,014 | $317.0K | 0.2% | – |
| Cybin Ord23256X100 | COM | 850,000 | $230.3K | 0.1% | – |
| Maat Pharma Saca00BNRR5C1 | COMM | 1,362 | $9.75K | <0.1% | – |